6 Best Peptides for Pressure Ulcers (Bedsores)

What to Know Before Choosing a Peptide for Pressure Ulcers

Pressure ulcers, also called bedsores or decubitus ulcers, form when sustained pressure cuts off blood flow to skin and underlying tissue, triggering a cascade of ischemia, cell death, and tissue breakdown. Standard care relies on pressure relief, wound debridement, and dressings. What is driving growing interest in peptides is that several of them target the exact biological failures at the root of a non-healing wound: the inability to grow new blood vessels into ischemic tissue, stalled collagen production, and the chronic inflammatory state that keeps a wound from progressing to repair.

Every compound in this list earned its place by meeting one criterion: people use it for pressure ulcer healing, or are actively discussing using it. That includes compounds available over the counter, compounds available only through research channels, and everything in between. The evidence for each is stated honestly inside its entry rather than used as a gate for inclusion. A compound with only community-reported use belongs on a complete list; omitting it would leave out exactly the information a reader who has been researching this goal came here to find.

The entries are numbered by how prominently each compound appears in published research and in documented real-world use for this goal. That is an ordering of the field, not a ranking of one option over another. The right compound for any individual depends on health history, wound stage, medications, and realistic accessibility, factors this article cannot weigh. That personalized layer is what the MyPeptidePal app is built to handle.

One field-wide note, stated once: as of 2026, no peptide is FDA-approved specifically for pressure ulcer treatment. The evidence base ranges from rigorous multicenter randomized controlled trials at one end to user-reported anecdotes at the other, and those differences are laid out plainly in each entry below.

1. Collagen Hydrolysates (Pro-Hyp and Hyp-Gly): The Best-Evidenced Oral Option

Collagen hydrolysates are oral peptide supplements derived from the enzymatic breakdown of animal collagen into small, bioactive fragments. The two fragments that drive wound-healing activity are Pro-Hyp (prolylhydroxyproline) and Hyp-Gly (hydroxyprolylglycine), specific dipeptides that behave as signaling molecules rather than simply as structural building blocks. Once ingested, Pro-Hyp reaches the dermis within roughly 30 minutes and acts as a chemotactic signal to fibroblasts, the cells responsible for producing collagen and rebuilding damaged tissue. It also promotes fibroblast multiplication and increases hyaluronic acid production, both of which support wound closure.

Of all the peptide options discussed for pressure ulcers, oral collagen hydrolysates carry the strongest direct human trial evidence in this specific indication. A 16-week double-blind multicenter randomized controlled trial compared a high-concentration collagen hydrolysate rich in Pro-Hyp and Hyp-Gly against a low-concentration version and a placebo. More than 71 percent of subjects in the high-concentration group showed measurable improvement in wound area, with significant improvements on standardized pressure ulcer healing scales compared to placebo. The placebo group showed no wound area improvement. A separate multicenter randomized controlled trial found significant reductions in ulcer severity scores after just two weeks of a collagen peptide drink compared to controls. A third placebo-controlled study in Stage 2 and Stage 3 pressure ulcer patients found that adding Pro-Hyp-containing peptides to standard treatment improved scores on three separate evaluation scales. Across studies, collagen peptide supplementation has been associated with wound healing efficiency improvements in the range of 10 to 30 percent and, in some trials, approximately double the healing rate by week eight compared to standard care alone.

Collagen hydrolysate supplements are available over the counter as dietary supplements, requiring no prescription. They are not FDA-approved as drug products for pressure ulcers, but they are sold legally in most markets as food supplements with a well-established safety profile. For people managing pressure ulcers who want a peptide option with genuine human trial backing and straightforward accessibility, this is the place the evidence most clearly points.

2. TB-500 (Thymosin Beta-4): The Most Clinically Validated Injectable

TB-500 is the synthetic analog of Thymosin Beta-4, a protein found in virtually every cell in the body that plays a central role in regulating actin, the structural protein that makes up much of the cell's internal framework. Think of actin as the scaffolding that gives cells their shape and lets them move. When tissue is damaged, Thymosin Beta-4 promotes the migration of repair cells to the injury site, accelerates the formation of new blood vessels through angiogenesis, and shifts the wound environment away from chronic inflammation toward active repair. Its clinical development for pressure ulcers is further along than any other injectable peptide in this space.

Two Phase II clinical trials have been completed using topical Thymosin Beta-4 formulations specifically for pressure ulcers. One randomized, double-blind, placebo-controlled dose-escalation study evaluated both safety and efficacy, and the results pointed toward approximately one month faster wound closure compared to placebo. The picture is not entirely clean: a more recent trial testing topical gels at various concentrations found no statistically significant difference versus placebo overall, though healing trends at intermediate doses suggested that formulation and concentration matter considerably. The honest summary is that the Phase II data is real, the signal is not yet definitive, and dose optimization appears to be the key variable the research is still working through.

In community protocols, TB-500 is well-regarded among people with spinal cord injuries and others managing difficult pressure wounds. Users in communities focused on spinal cord injury report it as a compound worth considering for pressure sore healing, and it appears frequently in injection-based peptide guides for this population. TB-500 is not FDA-approved for any human indication and is classified as research-use only. It is banned by the World Anti-Doping Agency. An absolute contraindication applies for anyone with active malignancy, because the same angiogenic mechanism that helps heal wounds also carries risk of stimulating cancer cell growth.

3. GHK-Cu (Copper Tripeptide-1): The Topical Skin Repair Staple

GHK-Cu is a naturally occurring human plasma tripeptide, the sequence glycine-histidine-lysine, chelated with a copper ion. It is one of the few peptides on this list that the body actually produces on its own; levels decline significantly with age, which is part of what makes topical application and supplementation interesting from a tissue-repair standpoint. Copper is an essential cofactor for the enzymes that cross-link collagen and elastin, so GHK-Cu delivers both the signaling peptide and the mineral it needs to activate collagen synthesis in a single molecule. It also attracts immune cells to wound sites, promotes new blood vessel growth, and remodels the extracellular matrix, the molecular scaffold that gives tissue its structural integrity.

The human evidence for GHK-Cu in skin wound healing is real but graded at a level some clinical reviewers describe as low to very low, primarily because most of the supporting trials are small and the field has not produced large multicenter randomized controlled trials comparable to those behind collagen hydrolysates. One clinical review found a roughly 3.9-fold higher healing rate with topical copper tripeptide gel compared to controls. That is a meaningful signal, though the study size limits how much weight it can carry on its own. In terms of the compounds people actually use for pressure ulcer recovery, GHK-Cu is one of the most commonly reached for in topical form. Community reports also include experimental injectable use combined with other repair peptides, particularly among people managing severe wounds who are already using multiple compounds. The topical route has a clean safety profile; injectable use at the doses discussed in community protocols has not been studied in controlled human trials for this indication.

GHK-Cu is available without a prescription as a topical product in many markets, sold under cosmetic and research classifications. It is not FDA-approved as a drug for pressure ulcers. For people looking for a topically accessible option with a genuine tissue-repair mechanism and some human evidence behind it, this is one of the more practical choices on the list.

4. BPC-157 (Body Protection Compound-157): The Preclinical Frontrunner

BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a protective protein naturally found in human gastric juice. It has been studied more extensively than almost any other peptide in this space, with well over 400 published preclinical studies examining its effects across tissue types. The breadth of that research is what drives its reputation: it activates growth factor signaling pathways that promote angiogenesis, meaning the formation of new blood vessels into ischemic tissue, which is directly relevant to the core problem in pressure ulcer formation. It also demonstrates anti-inflammatory properties and a broad regenerative profile across connective tissue, muscle, and nerve.

The gap between the preclinical evidence and the human trial record is substantial and worth stating plainly. As of 2026, no randomized controlled trial in humans has evaluated BPC-157 for pressure ulcer healing. The only human study in the literature is a small retrospective analysis of 16 participants with knee injuries, not pressure ulcers, and the results were difficult to interpret given the natural healing timeline. What drives its prominence in community discussions for this goal is not clinical trial data but rather a large volume of user-reported experience, particularly among people with spinal cord injuries managing wounds with limited standard-care options. Reports from this community describe reduced pain and inflammation, accelerated closure of necrotic wounds, and cessation of muscle spasms alongside wound healing, though these accounts are observational and uncontrolled. Independent observers have noted that marketing incentives from online resellers and the placebo effect are plausible confounding factors in some of that anecdotal reporting.

BPC-157 is not FDA-approved for any human use. It is classified as research-use only, is banned by the World Anti-Doping Agency, and is considered illegal for human consumption in the US and Canada under current regulatory frameworks. It is sold through online research-chemical channels without oversight of purity or sterility. The contraindication for active malignancy applies here as well, for the same angiogenic reasons as TB-500. The honest picture is that the mechanism is compelling, the preclinical data is extensive, and the human evidence for pressure ulcer healing specifically is currently absent.

5. LL-37: The Antimicrobial Peptide With a Healing Side

LL-37 is a human host-defense peptide, part of the cathelicidin family, that the immune system produces naturally to protect against bacterial invasion. What makes it relevant to pressure ulcers is a dual function most wound peptides do not share: it disrupts bacterial membranes directly, including those of treatment-resistant organisms like MRSA, while simultaneously promoting the wound-healing cascade through angiogenesis and macrophage polarization. That last mechanism involves shifting macrophages from the inflammatory M1 state to the tissue-repairing M2 state. Macrophages are immune cells that act as the wound's cleanup crew and repair coordinators, and the M1-to-M2 shift is essentially flipping them from demolition mode to construction mode. This is particularly relevant to chronic pressure wounds, where a stalled inflammatory phase is often what prevents healing from progressing.

The clinical trial record for LL-37 is the most advanced among the antimicrobial peptides in the pressure ulcer space, though the completed human trials focused on venous leg ulcers rather than pressure ulcers specifically. A published clinical study found healing rate constants 3 to 6 times higher than placebo at lower doses in patients with chronic leg ulcers, with the compound described as safe and well-tolerated with mild local reactions. Phase III trials for venous leg ulcers were initiated in 2015. For pressure ulcers specifically, the evidence as of 2026 comes from animal models and from laboratory studies using LL-37-loaded hydrogels for deep tissue injuries; published human trial data in pressure ulcers is not yet available. People researching peptides for infected or difficult-to-heal pressure wounds discuss LL-37 as a compound of interest given its combination of antimicrobial action and angiogenic promotion.

LL-37 is not FDA-approved and is not widely available as a commercial product for consumer use in bedsore treatment. Access is primarily through clinical trial participation or specialized research channels. A relative contraindication applies for individuals with compromised immune function, given its mechanism of action in modulating immune response.

6. SR-0379: The Most Advanced Pipeline Compound

SR-0379 is a synthetic functional peptide developed specifically as a wound-healing therapeutic, with the most advanced regulatory pipeline position of any novel peptide being studied for pressure ulcers as of 2026. Its Phase II trials reported no local adverse events, no systemic safety concerns, and only unrelated incidental findings among participants. Based on those results, a Phase III placebo-controlled, double-blind clinical trial has been initiated in Japan, with pressure ulcers, diabetic ulcers, and leg ulcers listed as explicit indications. That Phase III status applied to pressure ulcers specifically is a distinction no other peptide on this list currently holds.

SR-0379 sits at the end of this list rather than the top despite that pipeline position because it is not commercially available and is not something people are currently using outside of clinical trial settings. It belongs on a complete list because anyone who has spent time researching the pressure ulcer peptide landscape encounters it, and because its Phase III status signals where the clinical science is heading. No community-based use or protocol discussion of SR-0379 has emerged in the way it has for BPC-157 or TB-500. The evidence here is early clinical and regulatory rather than community-reported, with the key Phase III outcome data not yet available.

For anyone following the development of peptide-based wound care as a field rather than looking for something accessible immediately, SR-0379 is the compound to track. Its explicit focus on pressure ulcers in a properly powered Phase III trial means it will either become the most rigorously validated option in this space or contribute important data about why early-stage signals do not always translate to clinical benefit at scale.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for treating pressure ulcers?

As of 2026, no peptide is FDA-approved specifically for pressure ulcer treatment. The only FDA-approved peptide or growth factor for wound healing is becaplermin, which is approved for diabetic neuropathic ulcers only, not pressure ulcers. The compounds on this list range from over-the-counter dietary supplements like oral collagen hydrolysates to research-only injectables, and none carry a pressure-ulcer-specific drug approval in the United States.

What is the difference between topical and injectable peptides for wound healing?

Topical peptides like GHK-Cu and the Thymosin Beta-4 gel formulations tested in clinical trials are applied directly to or around the wound site, working by interacting with local skin cells, fibroblasts, and blood vessel-forming cells in the tissue. Injectable compounds like BPC-157 and TB-500 are administered subcutaneously and travel through the bloodstream to act systemically, which gives them reach beyond the wound surface but also introduces more significant regulatory and safety considerations. Oral collagen hydrolysates work through a third route, with bioactive dipeptides absorbed through the gut and signaling fibroblasts after reaching the dermis through circulation.

Is BPC-157 safe to use for a pressure ulcer?

BPC-157 has no published randomized controlled trial data in humans for pressure ulcer healing as of 2026, so its safety and effectiveness in this specific use remain unestablished by clinical standards. It is classified as research-use only, considered illegal for human consumption in the United States and Canada under current regulations, and banned by the World Anti-Doping Agency. Anyone with active malignancy should not use it, as its mechanism of stimulating blood vessel growth carries a risk of promoting cancer cell proliferation.

How long does peptide support for wound healing typically take to show results?

This varies considerably depending on the compound and the route of administration. In the collagen hydrolysate randomized controlled trials that showed the clearest results, meaningful improvements in wound healing scores appeared within two weeks in some studies and over 16 weeks in others. Users of injectable compounds like TB-500 and BPC-157 commonly report noticing changes over weeks to a few months in community accounts, though those timelines are observational rather than measured outcomes. The stage and complexity of the pressure ulcer also matters considerably, since a Stage 2 wound and a full-thickness Stage 4 wound with necrosis present fundamentally different healing challenges.

Can peptides be used alongside standard pressure ulcer wound care?

In the clinical trials that showed benefit, collagen hydrolysates were added to standard wound care rather than used in place of it, and the improvements measured were over and above what standard care achieved alone. That additive model, where peptide support layers onto pressure relief, debridement, and appropriate dressings, is how the evidence-based options have been studied. No peptide in the current research replaces the foundational work of offloading pressure, managing infection, and maintaining a moist wound environment.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for pressure ulcers (bedsores) in one place.